A Combined Activation Mechanism for the Glucagon Receptor
Total Page:16
File Type:pdf, Size:1020Kb

Load more
Recommended publications
-
Corticotropin-Releasing Hormone Physiology
European Journal of Endocrinology (2006) 155 S71–S76 ISSN 0804-4643 Corticotropin-releasing hormone physiology Joseph A Majzoub Division of Endocrinology, Children’s Hospital Boston, Thomas Morgan Rotch Professor of Pediatrics, Harvard Medical School, 300 Longwood Avenue, Boston, Massachusetts 02115, USA (Correspondence should be addressed to J A Majzoub; Email: [email protected]) Abstract Corticotropin-releasing hormone (CRH), also known as corticotropin-releasing factor, is a highly conserved peptide hormone comprising 41 amino acid residues. Its name derives from its role in the anterior pituitary, where it mediates the release of corticotropin (ACTH) leading to the release of adrenocortical steroids. CRH is the major hypothalamic activator of the hypothalamic–pituitary– adrenal (HPA)axis. Major functions of the HPAinclude: (i) influencing fetal development of major organ systems including lung, liver, and gut, (ii) metabolic functions, including the maintenance of normal blood glucose levels during the fasting state via glycogenolysis and gluconeogenesis, (iii) modulation of immune function, and (iv) maintenance of cardiovascular tone. In addition, CRH, acting both directly and via the HPA, has a role in regulating several neuroendocrine functions including behavior, food intake, reproduction, growth, immune function, and autonomic function. CRH has been localized to the paraventricular nucleus (PVN) of the hypothalamus, which projects to the median eminence and other hypothalamic and midbrain targets. The CRH gene is composed of two exons. The CRH promoter contains a cAMP-response element, and the intron contains a restrictive element-1/neuron restrictive silencing element (RE-1/NRSE) sequence. Recently, a family of CRH-related peptides, termed the urocortins, has been identified. -
The Activation of the Glucagon-Like Peptide-1 (GLP-1) Receptor by Peptide and Non-Peptide Ligands
The Activation of the Glucagon-Like Peptide-1 (GLP-1) Receptor by Peptide and Non-Peptide Ligands Clare Louise Wishart Submitted in accordance with the requirements for the degree of Doctor of Philosophy of Science University of Leeds School of Biomedical Sciences Faculty of Biological Sciences September 2013 I Intellectual Property and Publication Statements The candidate confirms that the work submitted is her own and that appropriate credit has been given where reference has been made to the work of others. This copy has been supplied on the understanding that it is copyright material and that no quotation from the thesis may be published without proper acknowledgement. The right of Clare Louise Wishart to be identified as Author of this work has been asserted by her in accordance with the Copyright, Designs and Patents Act 1988. © 2013 The University of Leeds and Clare Louise Wishart. II Acknowledgments Firstly I would like to offer my sincerest thanks and gratitude to my supervisor, Dr. Dan Donnelly, who has been nothing but encouraging and engaging from day one. I have thoroughly enjoyed every moment of working alongside him and learning from his guidance and wisdom. My thanks go to my academic assessor Professor Paul Milner whom I have known for several years, and during my time at the University of Leeds he has offered me invaluable advice and inspiration. Additionally I would like to thank my academic project advisor Dr. Michael Harrison for his friendship, help and advice. I would like to thank Dr. Rosalind Mann and Dr. Elsayed Nasr for welcoming me into the lab as a new PhD student and sharing their experimental techniques with me, these techniques have helped me no end in my time as a research student. -
Coordination of T Cell Activation and Migration Through Formation of the Immunological Synapse
Coordination of T Cell Activation and Migration through Formation of the Immunological Synapse MICHAEL L. DUSTIN Program in Molecular Pathogenesis, Skirball Institute of Biomolecular Medicine and the Department of Pathology, New York University School of Medicine, New York, New York 10016, USA ABSTRACT: T cell activation is based on interactions of T cell antigen receptors with MHC-peptide complexes in a specialized cell–cell junction between the T cell and antigen-presenting cell—the immunological synapse. The immunolog- ical synapse coordinates naïve T cell activation and migration by stopping T cell migration with antigen-presenting cells bearing appropriate major histo- compatibility complex (MHC) peptide complexes. At the same time, the immu- nological synapse allows full T cell activation through sustained signaling over a period of several hours. The immunological synapse supports activation in the absence of continued T cell migration, which is required for T cell activa- tion through serial encounters. Src and Syk family kinases are activated early in immunological synapse formation, but this signaling process returns to the basal level after 30 min; at the same time, the interactions between T cell re- ceptors (TCRs) and MHC peptides are stabilized within the immunological synapse. The molecular pattern of the mature synapse in helper T cells is a self- stabilized structure that is correlated with cytokine production and prolifera- tion. I propose that this molecular pattern and its specific biochemical constit- uents are necessary -
The New Aspects of Aminoacyl-Trna Synthetases
Vol. 47 No. 3/2000 821–834 QUARTERLY Review The new aspects of aminoacyl-tRNA synthetases. Maciej Szymañski, Marzanna Deniziak and Jan Barciszewski½ Institute of Bioorganic Chemistry of the Polish Academy of Sciences, 60-704 Poznañ, Poland Received: 29 December, 1999; revised: 24 May, 2000; accepted: 02 June, 2000 Key words: aminoacylation, aminoacyl-tRNA synthetases, protein biosynthesis, tRNA Aminoacyl-tRNA synthetases (AARS) are essential proteins found in all living organ- isms. They form a diverse group of enzymes that ensure the fidelity of transfer of ge- netic information from the DNA into the protein. AARS catalyse the attachment of amino acids to transfer RNAs and thereby establish the rules of the genetic code by virtue of matching the nucleotide triplet of the anticodon with its cognate amino acid. Here we summarise the effects of recent studies on this interesting family of multifunctional enzymes. The universal genetic code is established in a only components of the gene expression appa- single aminoacylation reaction of transfer ri- ratus that function at the interface between bonucleic acids (tRNAs). The reaction is nucleic acids and proteins. This leads to three catalysed by the family of aminoacyl-tRNA interesting aspects of studies on amino- synthetases (AARS) each of which activates acyl-tRNA synthetases: (i) the mechanism of an amino acid by binding to ATP and trans- amino acid recognition and chemical activa- fers it to the 3¢ end of the cognate tRNA. The tion, (ii) the specificity of tRNA recognition, conservation of the genetic code suggests that and (iii) the origin and evolution of AARS [3]. -
Lymphocyte-Activation Gene 3 (LAG-3) Immune Pathway
Lymphocyte-Activation Gene 3 (LAG-3) About LAG-3 LAG-3 Lymphocyte-activation gene 3 (LAG-3) is an immune checkpoint receptor protein found on the cell surface of effector T cells and regulatory T cells (Tregs) and functions to control T cell response, activation and growth.1 TCR T cells are a type of white blood cell that are part of the immune system. Activation of cytotoxic T cells by antigens enables them to 1 kill unhealthy or foreign cells. Inactive T cell Antigen MHC Dendritic cell (APC) LAG-3 and LAG-3 and LAG-3 and Immune Function T Cell Exhaustion Cancer • After a T cell is activated to kill its • However, in certain situations where T • Because of its critical role in regulating target cell, LAG-3 expression is cells experience prolonged exposure to an exhaustion of cytotoxic T cells and Treg increased to turn off the immune antigen, such as cancer or chronic function, LAG-3 has become a target of response, so that the T cell does not go infection, the T cells become desensitized study in the cancer field. on to attack healthy cells.2 and lose their ability to activate and multiply in the presence of the antigen.4 • In cancer, LAG-3 expressing exhausted • Inhibition of the immune response is cytotoxic T cells and Tregs expressing accomplished through activation of • The desensitized T cell will also LAG-3 gather at tumor sites.5,6 the LAG-3 pathway, which can occur progressively fail to produce cytokines via binding of LAG-3 to a type of (proteins that assist in the immune • Preclinical studies suggest that inhibiting antigen-presenting complex called response) and kill the target cells.4 LAG-3 allows T cells to regain their MHC II. -
G Protein-Coupled Receptors
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. British Journal of Pharmacology (2015) 172, 5744–5869 THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: G protein-coupled receptors Stephen PH Alexander1, Anthony P Davenport2, Eamonn Kelly3, Neil Marrion3, John A Peters4, Helen E Benson5, Elena Faccenda5, Adam J Pawson5, Joanna L Sharman5, Christopher Southan5, Jamie A Davies5 and CGTP Collaborators 1School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK, 2Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK, 3School of Physiology and Pharmacology, University of Bristol, Bristol, BS8 1TD, UK, 4Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK, 5Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/ 10.1111/bph.13348/full. G protein-coupled receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. -
Neuropeptide-Induced Contraction and Relaxation of the Mouse
Proc. Natl. Acad. Sci. USA Vol. 81, pp. 625-629, January 1984 Physiological Sciences Neuropeptide-induced contraction and relaxation of the mouse anococcygeus muscle (neurohypophysial peptides/neurotensin/thyrotropin-releasing hormone/urotensin i/vasoactive intestinal polypeptide) ALAN GIBSON*, HOWARD A. BERNtt, MICHAEL GINSBURG*, AND JACK H. BOTTING* *Department of Pharmacology, Chelsea College, University of London, Manresa Road, London SW3 6LX, United Kingdom; and tDepartment of Zoology and Cancer Research Laboratory, University of California, Berkeley, CA 94720 Contributed by Howard A. Bern, September 26, 1983 ABSTRACT Isometric tension responses to neuropeptides fects of a wide range of neuropeptides on tone of the mouse were recorded from anococcygeus muscles isolated from male anococcygeus in vitro. mice. This smooth muscle tissue is innervated by inhibitory nonadrenergic, noncholinergic nerves that resemble, ultra- MATERIALS AND METHODS structurally, the peptidergic neurons of the gastrointestinal Male mice (LACA strain from A. Tuck & Son, Battles- tract; the physiological function of the anococcygeus is not bridge, Essex, U.K.; 25-35 g) were stunned and bled. Both known. Slow sustained contractions were produced by oxyto- anococcygeus muscles were dissected from the animal and cin (0.2-20 nM), [Arg8]vasopressin (0.4-200 nM), and [Arg]- set up in series, joined at the point of unification on the ven- vasotocin (0.4-100 nM); the mouse anococcygeus is, therefore, tral rectum, in 1-ml glass organ baths that contained Krebs one of the few examples of nonvascular smooth muscle from bicarbonate solution (mM: NaCl, 118.1; KCI, 4.7; MgSO4, male mammals to respond to low concentrations of oxytocin 1.0; KH2PO4, 1.2; CaCl2, 2.5; NaHCO3, 25.0; glucose, 11.1). -
Structure-Function of the Glucagon Receptor Family of G Protein–Coupled Receptors: the Glucagon, GIP, GLP-1, and GLP-2 Receptors
Receptors and Channels, 8:179–188, 2002 Copyright c 2002 Taylor & Francis 1060-6823/02 $12.00 + .00 DOI: 10.1080/10606820290005155 Structure-Function of the Glucagon Receptor Family of G Protein–Coupled Receptors: The Glucagon, GIP, GLP-1, and GLP-2 Receptors P. L. Brubaker Departments of Physiology and Medicine, University of Toronto, Toronto, Ontario, Canada D. J. Drucker Department of Medicine, Banting and Best Diabetes Centre, Toronto General Hospital, Toronto, Ontario, Canada convertases results in the liberation of glucagon in the pancreatic The glucagon-like peptides include glucagon, GLP-1, and A cell, and GLP-1 and GLP-2 in the intestinal L cell and brain GLP-2, and exert diverse actions on nutrient intake, gastrointesti- (Mojsov et al. 1986; Orskov et al. 1987). As discussed below, nal motility, islet hormone secretion, cell proliferation and apopto- all three proglucagon-derived peptides (PGDPs) play impor- sis, nutrient absorption, and nutrient assimilation. GIP, a related member of the glucagon peptide superfamily, also regulates nutri- tant roles in the physiologic regulation of nutrient homeosta- ent disposal via stimulation of insulin secretion. The actions of these sis, through effects on energy intake and satiety, nutrient fluxes peptides are mediated by distinct members of the glucagon recep- through and across the gastrointestinal tract, and energy as- tor superfamily of G protein–coupled receptors. These receptors similation. Several of these biological activities are shared by exhibit unique patterns of tissue-specific expression, exhibit consid- a fourth glucagon-related peptide hormone, glucose-dependent erable amino acid sequence identity, and share similar structural and functional properties with respect to ligand binding and sig- insulinotropic peptide (GIP) (Table 1). -
Current Topics in Medicinal Chemistry, 2019, 19, 1399-1417 REVIEW ARTICLE
Send Orders for Reprints to [email protected] 1399 Current Topics in Medicinal Chemistry, 2019, 19, 1399-1417 REVIEW ARTICLE ISSN: 1568-0266 eISSN: 1873-4294 Impact Factor: Targeting the PAC1 Receptor for Neurological and Metabolic Disorders 3.442 The international journal for in-depth reviews on Current Topics in Medicinal Chemistry BENTHAM SCIENCE Chenyi Liao1, Mathilde P. de Molliens2, Severin T. Schneebeli1, Matthias Brewer1, Gaojie Song3, David Chatenet2, Karen M. Braas4, Victor May4,* and Jianing Li1,* 1Department of Chemistry, University of Vermont, Burlington, VT 05405, USA; 2INRS – Institut Armand-Frappier, 531 boul. des Prairies, Laval, QC H7V 1B7, Canada; 3Shanghai Key Laboratory of Regulatory Biology, Institute of Bio- medical Sciences and School of Life Sciences, East China Normal University, Shanghai, 200241, P.R. China; 4Department of Neurological Sciences, University of Vermont, Larner College of Medicine, 149 Beaumont Avenue, Bur- lington, VT 05405, USA Abstract: The pituitary adenylate cyclase-activating polypeptide (PACAP)-selective PAC1 receptor (PAC1R, ADCYAP1R1) is a member of the vasoactive intestinal peptide (VIP)/secretin/glucagon fam- ily of G protein-coupled receptors (GPCRs). PAC1R has been shown to play crucial roles in the central and peripheral nervous systems. The activation of PAC1R initiates diverse downstream signal transduc- tion pathways, including adenylyl cyclase, phospholipase C, MEK/ERK, and Akt pathways that regu- late a number of physiological systems to maintain functional homeostasis. Accordingly, at times of tissue injury or insult, PACAP/PAC1R activation of these pathways can be trophic to blunt or delay apoptotic events and enhance cell survival. Enhancing PAC1R signaling under these conditions has the potential to mitigate cellular damages associated with cerebrovascular trauma (including stroke), neu- A R T I C L E H I S T O R Y rodegeneration (such as Parkinson’s and Alzheimer's disease), or peripheral organ insults. -
An in Vitro Approach to Detect Metabolite Toxicity Due to CYP3A4
Toxicology 216 (2005) 154–167 An in vitro approach to detect metabolite toxicity due to CYP3A4-dependent bioactivation of xenobiotics Luisella Vignati ∗, Elisa Turlizzi 1, Sonia Monaci, Pietro Grossi, Ruben de Kanter, Mario Monshouwer 2 Department of Pre-Clinical Development, Nerviano Medical Sciences S.r.l., V.le Pasteur, 10, 20014, Nerviano, MI, Italy Received 22 June 2005; received in revised form 3 August 2005; accepted 3 August 2005 Available online 19 September 2005 Abstract Many adverse drug reactions are caused by the cytochrome P450 (CYP) dependent activation of drugs into reactive metabolites. In order to reduce attrition due to metabolism-mediated toxicity and to improve safety of drug candidates, we developed two in vitro cell-based assays by combining an activating system (human CYP3A4) with target cells (HepG2 cells): in the first method we incubated microsomes containing cDNA-expressed CYP3A4 together with HepG2 cells; in the second approach HepG2 cells were transiently transfected with CYP3A4. In both assay systems, CYP3A4 catalyzed metabolism was found to be comparable to the high levels reported in hepatocytes. Both assay systems were used to study ten CYP3A4 substrates known for their potential to form metabolites that exhibit higher toxicity than the parent compounds. Several endpoints of toxicity were evaluated, and the measurement of MTT reduction and intracellular ATP levels were selected to assess cell viability. Results demonstrated that both assay systems are capable to metabolize the test compounds leading to increased toxicity, compared to their respective control systems. The co-incubation with the CYP3A4 inhibitor ketoconazole confirmed that the formation of reactive metabolites was CYP3A4 dependent. -
Glucagon-Like Peptide-1 and Its Class BG Protein–Coupled Receptors
1521-0081/68/4/954–1013$25.00 http://dx.doi.org/10.1124/pr.115.011395 PHARMACOLOGICAL REVIEWS Pharmacol Rev 68:954–1013, October 2016 Copyright © 2016 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license. ASSOCIATE EDITOR: RICHARD DEQUAN YE Glucagon-Like Peptide-1 and Its Class B G Protein–Coupled Receptors: A Long March to Therapeutic Successes Chris de Graaf, Dan Donnelly, Denise Wootten, Jesper Lau, Patrick M. Sexton, Laurence J. Miller, Jung-Mo Ahn, Jiayu Liao, Madeleine M. Fletcher, Dehua Yang, Alastair J. H. Brown, Caihong Zhou, Jiejie Deng, and Ming-Wei Wang Division of Medicinal Chemistry, Faculty of Sciences, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands (C.d.G.); School of Biomedical Sciences, University of Leeds, Leeds, United Kingdom (D.D.); Drug Discovery Biology Theme and Department of Pharmacology, Monash Institute of Pharmaceutical Sciences, Parkville, Victoria, Australia (D.W., P.M.S., M.M.F.); Protein and Peptide Chemistry, Global Research, Novo Nordisk A/S, Måløv, Denmark (J.La.); Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Scottsdale, Arizona (L.J.M.); Department of Chemistry and Biochemistry, University of Texas at Dallas, Richardson, Texas (J.-M.A.); Department of Bioengineering, Bourns College of Engineering, University of California at Riverside, Riverside, California (J.Li.); National Center for Drug Screening and CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China (D.Y., C.Z., J.D., M.-W.W.); Heptares Therapeutics, BioPark, Welwyn Garden City, United Kingdom (A.J.H.B.); and School of Pharmacy, Fudan University, Zhangjiang High-Tech Park, Shanghai, China (M.-W.W.) Downloaded from Abstract. -
Vaccine Immunology Claire-Anne Siegrist
2 Vaccine Immunology Claire-Anne Siegrist To generate vaccine-mediated protection is a complex chal- non–antigen-specifc responses possibly leading to allergy, lenge. Currently available vaccines have largely been devel- autoimmunity, or even premature death—are being raised. oped empirically, with little or no understanding of how they Certain “off-targets effects” of vaccines have also been recog- activate the immune system. Their early protective effcacy is nized and call for studies to quantify their impact and identify primarily conferred by the induction of antigen-specifc anti- the mechanisms at play. The objective of this chapter is to bodies (Box 2.1). However, there is more to antibody- extract from the complex and rapidly evolving feld of immu- mediated protection than the peak of vaccine-induced nology the main concepts that are useful to better address antibody titers. The quality of such antibodies (e.g., their these important questions. avidity, specifcity, or neutralizing capacity) has been identi- fed as a determining factor in effcacy. Long-term protection HOW DO VACCINES MEDIATE PROTECTION? requires the persistence of vaccine antibodies above protective thresholds and/or the maintenance of immune memory cells Vaccines protect by inducing effector mechanisms (cells or capable of rapid and effective reactivation with subsequent molecules) capable of rapidly controlling replicating patho- microbial exposure. The determinants of immune memory gens or inactivating their toxic components. Vaccine-induced induction, as well as the relative contribution of persisting immune effectors (Table 2.1) are essentially antibodies— antibodies and of immune memory to protection against spe- produced by B lymphocytes—capable of binding specifcally cifc diseases, are essential parameters of long-term vaccine to a toxin or a pathogen.2 Other potential effectors are cyto- effcacy.